January 2024 in “Deleted Journal” Radiation cystitis patients need better monitoring and early treatment due to higher readmission rates.
1 citations
,
January 1995 in “Journal of Investigative Dermatology” RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.
January 2012 in “Hacettepe University Institutional Repository (hacettepe.edu.tr)” Microbeam Radiation Therapy is effective, but using a linear accelerator reduces its benefits.
1 citations
,
February 2002 in “Oncology Times” Intravenous arsenic is safe and effective for treating certain blood cancers.
15 citations
,
July 2009 in “Biomedical Chromatography” A reliable method was developed to measure aristolochic acid-I in rat blood.
1 citations
,
May 2021 in “Thyroid Research and Practice” Short-term side effects of low-dose radioactive iodine therapy are common but temporary.
January 2024 in “Bioanalysis” January 2015 in “Journals & Books Hosting (International Knowledge Sharing Platform)” Compound 1 showed promising anticancer activity.
July 2022 in “Zenodo (CERN European Organization for Nuclear Research)” 46 citations
,
May 2021 in “Stem Cell Research & Therapy” Strontium ranelate helps cartilage growth by blocking a specific cell pathway.
3 citations
,
April 2012 in “Osteoporosis International” A woman experienced hair loss after taking strontium ranelate for osteoporosis.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
114 citations
,
October 2009 in “Gastroenterology” Zinc is crucial for nutrition, especially in patients with specific health conditions, and requires careful supplementation and monitoring.
17 citations
,
October 2006 in “Molecular and Cellular Endocrinology” The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
December 2023 in “Ukraïnsʹkij žurnal sučasnih problem toksikologìï/Ukraïnsʹkij Žurnal Sučasnih Problem Toksikologìï” Better diagnosis and control of thallium poisoning are needed to prevent severe outcomes.
14 citations
,
March 1987 in “Journal of Investigative Dermatology”
1 citations
,
November 2025 in “Clinical Chemistry and Laboratory Medicine (CCLM)” A new method accurately measures DHEAS in blood, improving on current tests.
11 citations
,
April 2021 in “Advanced synthesis & catalysis” PXX is an effective and affordable photocatalyst for creating new chemical bonds in organic synthesis.
5 citations
,
March 2008 in “DMW - Deutsche Medizinische Wochenschrift” A man was poisoned with thallium, treated successfully, but still had some nerve issues after 6 months.
January 2018 in “ScholarWorks @UVM (University of Vermont)” Selenium in proteins helps prevent over-oxidation and supports chemical reversibility.
9 citations
,
July 2022 in “EMBO molecular medicine” Blocking certain immune signals can reduce skin damage from radiation therapy.
37 citations
,
October 2006 in “Steroids” New sulfur-containing steroid analogs show promise for more targeted medical treatments.
July 2024 in “Reactions Weekly”
1 citations
,
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib effectively regrows hair in severe alopecia areata, especially in adolescents.
30 citations
,
June 2017 in “Journal of cutaneous medicine and surgery” Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
1 citations
,
May 2007 in “Emergency medicine news” Dr. Marina Kovalevsky and her daughter were hospitalized for suspected politically motivated thallium poisoning in Moscow.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.